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Abstract
The English National Health Service is promoting concentration of the treatment of
patients with relatively rare and complex conditions into a limited number of spe-
cialist centres. If these patients are more costly to treat, the prospective payment
system based on Healthcare Resource Groups (HRGs) may need refinement because
these centres will be financially disadvantaged. To assess the funding implications
of this concentration policy, we estimate the cost differentials associated with caring
for patients that receive complex care and examine the extent to which complex care
services are concentrated across hospitals and HRGs. We estimate random effects
models using patient-level activity and cost data for all patients admitted to English
hospitals during the 2013/14 financial year and construct measures of the concen-
tration of complex services. Payments for complex care services need to be adjusted
if they have large cost differentials and if provision is concentrated within a few
hospitals. Payments can be adjusted either by refining HRGs or making top-up pay-
ments to HRG prices. HRG refinement is preferred to top-payments the greater the
concentration of services among HRGs.
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1 INTRODUCTION
Evidence indicates that outcomes following treatment are superior in places that perform more of the treatment in question
(Bachmann et al., 2003; Hillner, Smith, & Desch, 2000; Skipworth et al., 2010; Smith, 2002). Although a general causal link
between the volume of activity and outcomes has not been established definitively (Harrison, 2012), England is moving toward
concentrating the provision of some types of service in specialist centres rather than having them delivered in general hospitals
(NHS England, 2014a). For instance, from 2011 onwards, stroke patients in London have been admitted into one of eight
hyperacute stroke units, providing more complex care to stroke patients, which led to improved overall outcomes (Morris et al.,
2014). Concentration is particularly important for patients with relatively rare and complex care needs. Delivery of services for
such patients requires a skilled team of staff, and concentrating services in dedicated units is deemed the only way to ensure
that volumes are sufficient to ensure best possible outcomes (NHS Specialised Services, 2010).
Such concentration of services means that these skilled teams will treat patients that differ systematically from those treated
in general hospitals, differences that may impact the cost of treatment. If the reimbursement system does not account for such
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differences, hospitals that treat more costly patients will be financially disadvantaged, at the risk of undermining the policy
toward greater concentration.
In many countries, hospitals are reimbursed according to the amount and type of activity that they perform, with the type
of activity described using some form of Diagnosis-Related Groups (DRGs; Busse et al., 2013). The English classification is
known as Healthcare Resource Groups (HRGs) and, as with all DRG systems, is based on the underlying principle that the
constituent HRGs are both clinically meaningful and resource homogenous (Grašicˇ, Mason, & Street, 2015).
Resource homogeneity provides the rationale for reimbursing hospitals using HRGs under a prospective payment system,
with the HRG prices usually based on average costs as reported by hospitals that provide that service (O’Reilly et al., 2012).
This payment arrangement works well if variation in costs within HRGs is either not related to observable patient characteristics
or, if there is a relationship, patients are randomly distributed across hospitals. But if systematic variation in costs is associated
with particular groups of patients and hospitals, problems arise: the payment system may financially penalize hospitals treating
higher cost patients or simply deter hospitals from treating patients expected to have higher costs (Dranove, 1987).
Systematic variation will arise if treatment costs for patients who receive complex care services are higher than for other
patients allocated to the same HRG. We assess this possibility by calculating the cost differential associated with providing
complex care services. Hospitals will face greater adverse financial consequences the greater the differential and the higher the
proportion of their patients who require complex care. To establish which hospitals are at risk of financial disadvantage, we
construct Gini coefficients to summarise the concentration of each type of complex care service among hospitals (Daidone &
D’Amico, 2009).
If there is evidence of systematic variation, there are two approaches to adjusting payments in order to mitigate adverse
financial consequences. The first is to recalculate the HRG price, so that a top-up payment is paid for those that receive complex
care with an offsetting price reduction for all other patients allocated to the same HRG. The price differential would reflect the
estimated cost differential for each particular type of complex care. This first option is easiest to implement because it requires
no change to the underlying architecture of the patient classification system.
The second option is to refine the underlying HRGs to which patients are allocated. Hafsteinsdottir and Siciliani set out the
theoretical implications of refinement in relation to two treatments, demonstrating that refinement is optimal if otherwise there
is a risk of under-provision of the more costly treatment (Hafsteinsdottir & Siciliani, 2010). We apply this reasoning to the
practical challenge of having to consider not just two but the hundreds of different treatments categorised by DRG or HRG
systems (Busse et al., 2013).
Refinement of HRGs is most appropriate when patients that receive complex care are concentrated in a small number of
existing HRGs. If patients are spread across many HRGs, subdividing them will generate many more HRGs, containing fewer
patients. If HRG refinement is coupled with a policy of concentrating complex services in fewer hospitals, there is a risk that
a single hospital provides all the care to patients in a particular HRG. In such circumstances, the price for that HRG will be
determined by just one hospital, with prospective payment collapsing to cost-based reimbursement. The option of refining
HRGs, then, becomes less attractive the more HRGs that complex care patients are spread across. To assess how patients are
distributed across HRGs, we calculate concentration ratios to show the concentration of each type of complex care activity
among HRGs (Siegfried, 1975).
Whether or not to refine HRGs requires making decisions about what size of cost differential is deemed material and about
how concentrated services need to be among hospitals and HRGs before refinement is considered. These are essentially policy
decisions but, for illustrative purposes, we show which complex care services would be candidates for either top-up payments
or refinement under different thresholds for the cost differentials and concentration measures.
In Section 2, we describe how receipt of complex care may have a differential impact on the costs of care for patients allocated
to the same HRG and the implications that this might have on hospital profitability. This motivates our empirical approach
to estimating cost differentials and in analysing the concentrations of complex care among hospitals and HRGs. We analyse
patient-level data for the 2013/14 financial year and describe these data in Section 3. Section 4 focuses on the results. The policy
implications of the results are discussed, limitations acknowledged, and conclusions drawn in Section 5.
2 EMPIRICAL FRAMEWORK
Every patient treated in hospital is allocated to a single HRG, which forms the basis by which the hospital is reimbursed for
the care provided. An individual patient i=1...I is allocated to a unique HRG h=1...H according to a set of observable patient
characteristics, denoted as vector X, including the type of procedure performed (OPCS codes), diagnoses (ICD10 codes),1 the
presence of complications and comorbidities, age, and gender (Grašicˇ, Mason, & Street, 2015).
1ICD10: International Statistical Classification of Diseases and Related Health Problems 10th Revision; OPCS: Office for Population Censuses and Surveys
Classification of Surgical Operations and Procedures
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Patients allocated to the same HRG may differ according to whether they received some form of complex care, identifiable
in England according to a set of identification rules known as Prescribed Specialised Services (PSS; NHS England, 2014b).
For ease of exposition, we assume initially that there is only one type of complex care and denote s̄ to indicate that a patient
received complex care and s to denote that they did not, such that S ∈ (s, s̄).
Ceteris parabis for patients allocated to any representative HRG, the cost of hospital care cih is likely to be higher for patients
who required complex care than for those that did not, such that cih(si,Xih) < cih(s̄i,Xih). We anticipate that receipt of complex
care will have a proportionate effect �h on costs such that �hcih(si,Xih) = cih(s̄i,Xih). The national average cost of an HRG ch
will therefore depend on the proportion of patients nationally � who receive complex care, such that
ch = � × ch(s̄,Xh) + (1 − � × ch(s,Xh). (1)
In many prospective payment systems, the price ph paid for each patient allocated to a particular HRG is based on average
costs (Schreyögg, Stargardt, Tiemann, & Busse, 2006). Thus expected profit (i.e., excess revenue) per patient amounts to �h =
ph − ch = 0. But expected profit will differ from hospital to hospital, if the proportion of complex care patients that the hospital
treats �k differs from the national average �. So if �k ≠ � then chk ≠ ch, with the average profit per patient for hospital k = 1 … K
given by
�hk = ch(s,Xh)[�(�h − 1) + �k(1 − �h)]. (2)
Profit is negative and increasing in magnitude the larger �k relative to � and the larger �h relative to 1. Thus, if providing
complex care does increase costs, then a policy designed to concentrate complex care activity among fewer hospitals risks being
financially punitive to those hospitals providing complex care. Our empirical strategy is, therefore, to estimate the proportionate
additional cost �h associated with provision of complex care service and to assess the proportion of complex care activity �k
undertaken by each hospital.
To do this, we use the reference cost data, a collation of HRG costs reported in a standardised format by official mandate by
all English hospitals to the Department of Health (Department of Health, 2012). As in most countries with prospective payment
systems (Schreyögg et al., 2006), for each HRG, the cost information comprises two elements: a base cost cb
h
for those patients
with a typical length of stay (LoS) for their HRG and an excess per diem cost ce
h
for each extra day spent in hospital by patients
with an exceptionally long LoS for their HRG (Health and Social Care Information Centre, 2015). Thus, the full cost of hospital
treatment for each patient i allocated to HRG h and treated in hospital k takes the form:
cihk = c
b
ihk
+ ce
ihk
dihk, (3)
where dihk indicates the additional number of days that the patient stays in hospital above the typical LoS for their HRG. These
reported costs are converted into prices in a similar fashion to that adopted in other countries with a prospective payment system,
whereby a base price pb
h
is made for each patient according to the HRG to which they are allocated, and an additional per diem
price pe
h
is paid for each day spent in hospital beyond the LoS typical to the HRG (Schreyögg et al., 2006). In keeping with
these payment arrangements, we investigate whether the provision of complex care influences variation in either base costs or
additional per diem costs in separate regression models, denoting these costs as c∗
ihk
∈ (cb
ihk
, ce
ihk
).
The empirical challenge in estimating these costs is that patients are admitted to hospital for many different types of treatment
hence their categorisation to specific HRGs. One way to account for this diversity is to introduce a dummy variable for each
HRG, but because there are so many, categories2 estimation is cumbersome. The alternative is to standardise each patient’s cost
by the mean cost of all patients allocated to the same HRG (Daidone & Street, 2011a). Thus the dependent variable is defined as
y∗
ik
=
c∗
ihk
Zkc
∗
h
, (4)
where c∗
ihk
is the cost of patient i in HRG h in hospital k, and c∗
h
is the national mean cost for patients allocated to HRG h.
In the analyses that follow and in keeping with how prices in England and elsewhere are calculated, costs are also purged of
geographical variation in wages and in the cost of land and buildings (Mason, Street, Miraldo, & Siciliani, 2009; Zuckerman,
Welch, & Pope, 1990). This hospital-specific adjustment is denoted Zk.
3
2In 2013/14 the HRG system comprised 2100 HRGs.
3The adjustment is made using the English Department of Health’s Market Forces Factor (MFF). https://www.gov.uk/government/uploads/system/uploads/
attachment_data/file/214906/PbR-and-the-MFF-in-2013-14.pdf.
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To estimate the cost differential associated with receipt of complex care, we regress y∗
ik
against a full set (n = 1 … N) of
complex care markers (Sn) indicating the type of complex care received (if any).
4 So, for any individual i, Sni = 1 if the patient
received complex care of type n, and 0 otherwise. The random effects model, recognising that patients are clustered within
hospitals, takes the form:
y∗
ik
= � +
N∑
n=1
�nSnik + uk + �ik, (5)
where �n are the parameters to be estimated. Costs will be related also to hospital efficiency uk (Laudicella, Olsen & Street,
2010; Street, Kobel, Thuilliez, & Renaud, 2012), which we assume acts like a scaling factor, increasing or decreasing the cost
of care for a particular patient, and which is not subject to reimbursement. Costs will also vary from one patient to another for
reasons that cannot be observed. These reasons are captured by �, a random error term assumed to have a normal distribution,
with E[�ik] = 0.
If the �̂n parameters are not significant explanators of variation in cost, they do not need to be taken into account in payment
design. But if positive and significant, a patient with complex care marker n has higher costs than do other patients allocated to
the same HRG. By defining the dependent variable as a ratio, we can calculate the percentage cost differential associated with
receipt of complex care (Daidone & Street, 2013). In order to derive the percentage increase in costs associated with receipt
of complex care, gn, we compute the marginal mean for both complex care and noncomplex care services (Daidone & Street,
2013):
gn =
E(yi|Sn = s̄, S) − E(yi|Sn = s, S)
E(yi|Sn = s, S) × 100. (6)
Even if patients receiving complex care treatment have higher costs, if the distribution of complex care across hospitals is
random, hospitals will not be financially disadvantaged in a systematic fashion. But hospitals treatingmore complex care patients
are at risk of receiving insufficient revenue to cover their costs. We assess the concentration of complex care patients by means
of a Gini coefficient, Gn, for each particular type of complex care n, calculated according to the formula:
Gn =
K + 1
K − 1
− 2 ×
∑K
k=1 �nkQnk
K(K − 1)�n
, (7)
where K is the number of hospitals, and �n is the mean proportion of complex care patients of type n across all hospitals. The
Gini coefficient ranges from 0 (no concentration) to 1 (complex care is concentrated in a single hospital). We rank all hospitals
according to their number of complex care patients Qnk, with the hospital performing the greatest amount ranked first. �k is the
rank of hospital k with Qnk patients receiving complex care of type n.
If the estimated coefficients �̂n are significant and patients are concentrated in particular hospitals, the payment system
needs to be revised in some way to avoid punitive financial consequences. There are two options: to refine the underlying
HRGs to account for the provision of complex care or to apply a compensatory top-up payment to either or both the base
and excess per diem prices. The choice will depend on the extent to which patients receiving complex care are concen-
trated within existing HRGs. If concentrated in a small number of HRGs, refinement of these HRGs might be feasible. But
if these patients are spread across multiple HRGs, subdividing each one will generate many HRGs, giving rise to two risks.
First, each group will contain too few patients for valid statistical comparisons, this being a key condition specified by the
architects of the original DRG system (Fetter, Shin, Freeman, Averill, & Thompson, 1980). Second, the fewer hospitals treat-
ing patients requiring complex care, the greater the risk that the payment system reduces to cost-based reimbursement. To
guard against these risks, when patients receiving complex care are spread across multiple HRGs, a top-up payment would
be preferred.
4It is possible for a patient to receive more than one type of complex care service. Receipt of multiple services may lead to correlation problems. How-
ever, the number of patients with multiple complex care services markers is very low and Variance Inflation Factors confirm that multi-collinearity is not
a problem.
BOJKE ET AL. 5
To assess the concentration of complex care services among different HRGs, we could also construct Gini coeffi-
cients. However, because of the large number of HRGs (h = 2100), the Gini coefficient will always be very close
to 1. Instead, we calculate concentration ratios analogous to the Four-Firm measures used to measure industry structure
(Siegfried, 1975).
The concentration ratio is the percentage of total complex care activity of type n allocated to the four HRGs that account for
the largest amount of this type of complex care and is calculated as
CR4n =
4∑
h=1
s̄nh, (8)
where s̄nh is the share of activity provided in the h-th largest HRG by volume of complex care activity of type n.
3 DATA
In order to assess the costs associated with hospitalised patients receiving complex care services, we analyse data from the
patient level Hospital Episode Statistics (HES) for 2013/14matched to reference cost (RC) data reported by all English hospitals.
These costs are purged of exogenous cost factors. The HES contains details about every patient treated in the English NHS
during the financial year. Each patient observation constitutes their time in hospital from admission to discharge.
We identify what type of complex care service, if any, each patient received by applying the set of PSS identification rules
(NHS England, 2014b). Information in each patient’s first diagnostic and all procedural fields is examined to ascertain whether
the ICD10 or OPCS codes designated in the PSS are present in their medical record. In general, these codes differ from those
used for HRG assignment. The PSS manual and accompanying spreadsheet5 set out identification rules for 143 groups of
complex care services, of which 69 relate to services for patients admitted to hospital (NHS England, 2014b). The PSS 2013-14
identification tool is available online.6
We match each patient’s HES record to the RC reported by their hospital in order to establish the base, cb
ihk
, and excess per
diem, ce
ihk
, costs of their hospital care. Only 4.1% of patients have excess per diem costs.7 Matching of costs to patients is done
through a combination of the hospital code, point of delivery (e.g., day case, elective, and nonelective), specialty (e.g., 300:
General Surgery) and HRG code.8
The matched HES and RC data yielded 12,474,184 patients, of which 792,974 received a complex care service of one form or
another. However, 25,362 (3.2%) of patients that received complex care were allocated to HRGs in which all patients received
complex care because the PSS rules coincided with those used to construct these HRGs. This was true, for instance, of almost
everyone having bone marrow transplantation, cochlear implants and bone anchoring hearing aids. Given that all those allocated
to these HRGs received complex care, there is no cost differential to estimate. Hence, patients allocated to HRGs in which
everyone received complex care are dropped from the analysis. This leaves an analytical sample of 12,403,818 patients, of which
766,204 received complex care.
4 RESULTS
In Table 1, we report the number of patients in the analysis for each complex care marker9 and the results of applying Equation 6
to the estimates derived from Equation 5, highlighting significant cost differentials (p < .0001). This shows, for example, that
41,389 patients (N base cost) received chemotherapy and that the base cost of their hospital care was 4% higher than otherwise
similar patients allocated to the same HRG. Of these patients, 202 (N per diem) stayed in hospital longer than typical for their
HRG, and their excess per diem cost was 15% higher than that for otherwise similar patients allocated to the same HRG. Many
hospitals provide chemotherapy, the Gini coefficient being 0.66, and patients receiving this service are allocated to only a
handful of HRGs, the four main HRGs (CR4) accounting for 98% of this complex care activity.
5http://www.hscic.gov.uk/media/11878/PS-201314-Identification-Code-Sets/xls/PS_2013_14_Prescribed_Services_Identification_Code_Sets_v1.1.xlsx.
6http://www.hscic.gov.uk/casemix/prescribedspecialisedservices
7Almost 1.4 m patients also have unbundled costs, these being associated with high cost services or procedures. These are paid for separately and, hence, are
omitted from the analyses.
8https://www.gov.uk/government/publications/reference-costs-guidance-for-2011-12
9Results are not shown if fewer than 300 patients nationally received this type of complex care, of which there were 14 types; results for these complex care
markers are available from the authors on request.
6
B
O
JK
E
E
T
A
L
.
TABLE 1 Patient numbers, regression results, and concentration measuresa
N base cost Base cost differential (%) N per diem Per diem differential (%) Gini CR4
Chemotherapy 41,389 4 202 15 0.66 0.98
PET-CTb 497 132 129 −2 0.95 0.11
Radiotherapy 10,536 37 822 4 0.97 0.86
Stereotactic radiosurgery 1,197 −112 9 −16 0.99 0.84
Teenage and young adults cancer 5,864 28 187 2 0.82 0.56
Rare cancers (adult) 30,019 17 1812 −3 0.72 0.42
Haemophilia 3,673 23 115 29 0.89 0.74
Women—complex minimal access gynaecology surgery 1,961 −8 13 2 0.77 0.59
Women—maternal medicine 41,612 9 1743 0 0.66 0.75
Spinal—spinal surgery 8,291 −14 667 −1 0.84 0.49
Neurosciences—neurology 121,574 10 6218 14 0.86 0.52
Neurosciences—neurosurgery 61,308 41 4441 3 0.92 0.24
Burns care 2,009 73 256 23 0.97 0.88
Cystic fibrosis 422 −9 8 −14 0.87 0.76
Renal services—access for dialysis 12,255 20 557 4 0.88 0.43
Renal services—renal Transplantation 8,793 −17 258 11 0.88 0.8
Cardiac—cardiac electrophysiology 6,028 −3 462 −10 0.88 0.73
Cardiac—inherited heart disorders 4,162 16 262 0 0.69 0.43
Cardiac—cardiac surgery 27,354 22 1432 −7 0.9 0.26
Cardiac—PPCI and Structural Heart Diseasec 27,337 13 2086 −3 0.79 0.8
Cardiac—pulmonary hypertension 906 12 12 −3 0.93 0.7
Cardiac—cardiovascular magnetic resonance 1,483 60 240 10 0.93 0.27
Cardiac—other 19,567 2 814 3 0.68 0.47
Adult congenital heart disease 3,507 −14 126 −9 0.85 0.65
Cleft lip palate 2,275 −7 59 −2 0.95 0.7
Immunology 9,140 −9 27 25 0.92 0.95
Allergy 2,292 −22 0 0% 0.97 0.77
Hepatology and pancreatic 2,847 8 188 −2 0.84 0.6
Children—cancer 20,510 11 392 −1 0.9 0.7
Children—cardiac 7,283 18 501 18 0.85 0.42
Children—endocrinology 4,270 −8 20 65 0.96 0.85
Children—gastroenterology 54,635 4 2133 −1 0.72 0.33
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TABLE 1 Continued
N base cost Base cost differential (%) N per diem Per diem differential (%) Gini CR4
Children—haematology 1,754 8 43 −13 0.96 0.73
Children—neurosciences 11,010 24 528 −1 0.96 0.24
Children—ophthalmology 6,467 30 100 −2 0.8 0.31
Children—renal 7,205 −9 229 11 0.97 0.64
Children—respiratory 9,139 30 424 15 0.95 0.46
Children—rheumatology 7,376 −1 204 10 0.84 0.51
Children—surgery 59,543 15 5329 5 0.79 0.38
Respiratory—complex thoracic surgery 27,562 35 1200 4 0.9 0.32
Respiratory—management of central airway obstruction 2,206 47 127 31 0.84 0.38
Respiratory—interstitial lung disease 9,330 −2 468 −2 0.65 0.72
Respiratory—other 16,373 13 1609 0 0.6 0.2
Vascular Services 5,577 7 506 6 0.75 0.58
Colorectal—incontinence 1,270 −42 3 −43 0.95 0.77
Colorectal—transanal endoscopic microsurgery 497 55 2 −32 0.91 0.86
Orthopaedic surgery 1,628 20 196 −4 0.79 0.38
Morbid obesity surgery Ophthalmology 23,022 −2 729 −10 0.78 0.25
Haemoglobinopathy—sickle cell 10,813 10 601 7 0.95 0.73
Haemoglobinopathy—thalassaemia 8,121 0 7 34 0.9 1
Highly specialised 8,014 29 385 59 0.99 0.16
Total specialised patients 766,204 39,007
Total patients 12,403,818
aIncludes complex care services markers for which the sample is more than 300 patients.
bPositron emission tomography-computed tomography.
cPrimary Percutaneous coronary intervention.
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As shown in the column reporting the base cost differential, many, but not all, of the complex care markers are positive and
significant when considering base costs. The cost differential between those that do and do not receive complex care is more
than 10% for 26 markers; for 12 of these, the difference is more than 25%; and for 4 it is more than 50%, these being positron
emission tomography computed tomography (132% higher), burns care (73%), cardiovascular magnetic resonance (60%), and
colorectal transanal endoscopic microsurgery (55%).
The excess per diem cost differential between those that do and do not receive complex care is more than 10% for ninemarkers;
for four of these, the difference is more than 25%; and for 2, it is more than 50%, these being children’s endocrinology (65%)
and highly specialised care (59%).
The Gini coefficients show that most complex care services seem to be concentrated among relatively few hospitals with a
mean value of Gini = 0.88. The minimum Gini coefficient is 0.60 (for respiratory—other) and the maximum is 0.99 (highly
specialised). Given that complex care activity is generally highly concentrated within particular hospitals, it is clear that failing
to compensate for the additional costs of complex care activity would not affect all hospitals equally.
For a handful of complex care markers, the additional cost estimates are negative, suggesting that patients receiving these
forms of complex care are less costly than other patients allocated to the same HRG. This is particularly notable for stereotactic
radiosurgery (−112%), colorectal incontinence (−42%), and renal transplantation (−17%). Care is highly concentrated for these
services, the Gini coefficients being 0.99, 0.95, and 0.88 respectively. Those hospitals in which care these types of complex
care service are concentrated might benefit from economies of scale, in which case they would have lower differential costs.
There is previous research suggesting that hospitals specialising in fewer categories of medical services have lower costs (Farsi
& Filippini, 2008).
In Table 2, we report our estimates of the total costs at national level for those complex care markers for which estimates of
the additional costs were positive and significant. For the NHS as a whole, the additional costs associated with provision of
complex care amount to £588 m representing 3.5% of the funding allocated through the prospective payment system (Monitor,
2015). The national financial impact exceeds £70 m for three types of complex care these being neurosurgery (£157 m), cardiac
surgery (£79 m) and complex thoracic surgery (£75 m).
In Figure 1, we plot each of the complex care markers in terms of its national financial impact and the Gini coefficient
measuring hospital concentration. The above-mentioned three complex care markers stand out in the upper right corner because
these types of complex care are conducted in few hospitals (Gini > 0.8) and have a high national financial impact. Failure to
account for the additional costs associated with their complex care would therefore have a substantial punitive effect on those
few hospitals that provide these complex care services.
In view of these findings, there is a strong case for compensating complex care activity on the basis of the observed cost
differentials, and the impact of these higher costs may have on individual hospitals. We explore two options by which these
extra costs could be compensated. The current convention is to apply a top-up to existing HRGs (Monitor & NHS England,
2013), but it is also worth considering whether it would be preferable to further refine the underlying HRGs to which patients
receiving complex care are allocated (Hafsteinsdottir & Siciliani, 2010). To assess these alternatives, we calculate the CR4 ratio,
measuring the proportion of complex care services that are in the most common four HRGs. The CR4 ratios are reported in the
final column of Table 1.
The choice between whether to adopt top-up payments or refine HRGs requires making decisions about what size of cost
differential is deemed material and how concentrated services need to be among hospitals and HRGs before a split is considered.
For example, for illustrative purposes, suppose that the threshold for the cost differential is 10%, and for both the Gini and CR4,
it is >0.8. 26 of the 69 complex care services have a cost differential in excess of 10%. At the 0.8 concentration thresholds,
top-up payments to the HRG price would be considered for 23 of the 26 types of complex care. This payment would be made
in proportion to the estimated cost differential associated with the type of complex care in question with offsetting reductions
in the base price for other patients allocated to the same HRG. HRG splits would be considered for three of the 26 types of
complex care, namely, radiotherapy (Gini = 0.97 & CR4 = 0.86), burns care (Gini = 0.97 & CR4 = 0.88), and colorectal
transanal endoscopic microsurgery (Gini = 0.91 & CR4 = 0.86). With patients receiving these particular complex care service
being allocated to just a few HRGs, these might be subdivided to distinguish patients that receive complex care from those that
do not.
Figure 2 illustrates how the number of complex care services that are candidates for HRG refinement or top-up payments
varies according to decisions about the size of the cost differential and concentration measures. The graph shows four lines
indicating the number of complex care services with cost differentials in excess of 50%, 25%, 10%, and 5%. For each line, the
number of complex care services considered for either refinement or top-up payments can be identified according to thresholds
chosen for the two concentration measures. Thresholds (rounded to a single decimal place) are shown along each line if these
indicate a change in the number of complex care services considered for either HRG refinement or top-up payments.
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TABLE 2 Financial impact and refinement recommendationsa
Total Base cost
Gini CR4 value (£000) N nationally differential (%) Impact (£000) Recommendation
Chemotherapy 0.66 0.98 £34,112 782,697 4 £1,327
PET-CTb 0.95 0.11 £4,586 1,290 132 £6,040 Top-up
Radiotherapy 0.97 0.86 £54,589 101,472 37 £20,430 Split
Teenage and young adults cancer 0.82 0.56 £12,805 13,456 28 £3,579 Top-up
Rare cancers (adult) 0.72 0.42 £132,350 64,478 17 £22,775 Top-up
Haemophilia 0.89 0.74 £5,444 5,585 23 £1,229 Top-up
Women—maternal medicine 0.66 0.75 £44,930 45,142 9 £3,947
Neurosciences—neurology 0.86 0.52 £208,868 144,318 10 £21,308 Top-up
Neurosciences—neurosurgery 0.92 0.24 £383,066 79,986 41 £157,190 Top-up
Burns care 0.97 0.88 £20,910 6,797 73 £15,168 Split
Renal services—access for dialysis 0.88 0.43 £49,893 17,203 20 £10,084 Top-up
Cardiac—inherited heart disorders 0.69 0.43 £30,249 6,260 16 £4,767 Top-up
Cardiac—cardiac surgery 0.9 0.26 £365,229 43,488 22 £79,265 Top-up
Cardiac—PPCIc and structural heart disease 0.79 0.8 £189,369 50,482 13 £25,527 Split
Cardiac—pulmonary hypertension 0.93 0.7 £3,342 1,153 12 £391 Top-up
Cardiac—cardiovascular magnetic resonance 0.93 0.27 £22,560 6,123 60 £13,612 Top-up
Hepatology and pancreatic 0.84 0.6 £32,480 4,178 8 £2,455
Children—cancer 0.9 0.7 £65,046 55,693 11 £7,210 Top-up
Children—cardiac 0.85 0.42 £47,916 18,169 18 £8,660 Top-up
Children—gastroenterology 0.72 0.33 £136,175 82,217 4 £5,139
Children—haematology 0.96 0.73 £3,507 2,493 8 £290
Children—neurosciences 0.96 0.24 £40,557 16,824 24 £9,576 Top-up
Children—ophthalmology 0.8 0.31 £8,983 8,676 30 £2,727 Top-up
Children—respiratory 0.95 0.46 £14,490 11,825 30 £4,293 Top-up
Children—surgery 0.79 0.38 £312,937 137,885 15 £45,840 Top-up
Respiratory—complex thoracic surgery 0.9 0.32 £214,554 37,283 35 £74,736 Top-up
Respiratory—management of central airway obstruction 0.84 0.38 £11,300 3,428 47 £5,336 Top-up
Respiratory—other 0.6 0.2 £133,625 27,326 13 £17,791 Top-up
Vascular services 0.75 0.58 £76,998 7,742 7 £5,457
Colorectal—transanal endoscopic microsurgery 0.91 0.86 £1,437 543 55 £789 Split
Orthopaedic Surgery 0.79 0.38 £9,747 1,942 20 £1,992 Top-up
Haemoglobinopathy—sickle cell 0.95 0.73 £20,717 19,947 10 £2,025
Highly specialised 0.99 0.16 £22,453 12,067 29 £6,569 Top-up
Total £2,715,227 £587,524
aIncludes complex care markers for which the sample is more than 300 patients and where the cost differential is positive and significant.
bPositron emission tomography-computed tomography.
cPrimary Percutaneous coronary intervention.
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FIGURE 1 Gini coefficient and financial impact of of Prescribed Specialised Services markers
FIGURE 2 Complex care services considered for Healthcare Resource Groups refinement or top-up payments according to choices about the size
of the cost differential and concentration measures
5 CONCLUSIONS
The policy for the English NHS of concentrating complex care services in particular providers is designed to improve outcomes
for people with relatively rare and complex conditions. But the payment system needs to be aligned with this policy ambition
so that hospitals that provide complex care are not penalised financially for doing so.
There is no universally agreed definition of what constitutes complex care hospital care, but in England attempts have been
made to define complex care according to the presence of specific diagnoses and procedures in each patient’s medical record.
We have applied these complex care definitions to determine whether the receipt of complex care is associated with higher
costs relative to patients allocated to the same HRG who did not receive complex care. To do this, we estimate random effects
models using patient-level activity and cost data for all patients admitted to English hospitals during the 2013/14 financial year.
Compared to otherwise equivalent patients allocated to the same HRG, costs were more than 10% higher for patients receiving
26 (out of 69) types of complex care delivered in hospitals.
The existence of cost differentials is a necessary but not sufficient condition for refining the payment system. In addition, we
consider materiality, in terms of both the national financial impact and the number of hospitals that will be affected. These dual
aspects are important because, even though there may not be many patients nationally receiving a particular type of complex
care service, if these patients are concentrated in few hospitals, payments may have a material impact on their income and ability
to provide the service. For those complex care markers for which the estimated cost differential is deemed to have a material
impact, we explore two ways in which payment policy might be refined.
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First, HRGs might be refined so that they better separate higher cost patients that receive complex care from those that do
not (Hafsteinsdottir & Siciliani, 2010). If perfect separation can be achieved, the prices for HRGs in which everybody receives
complex care will adequately reflect the expected costs associated with complex care. This strategy is most easily adopted for
those types of complex care where patients are concentrated in a limited number of HRGs, evaluated here by calculating the
proportion of complex care activity concentrated among the four largest HRGs to which patients are assigned. If, by way of
illustration, the cost differential exceeds 10%, and the concentration measures exceed 0.8, HRG splits would be considered for
three types of complex care and top-up payments for 23 types. If these thresholds were gradually lowered, yet more HRGs would
be constructed to account for progressively more of these types of complex care services. But the risk of constructing ever more
refined HRGs is that the likelihood of one hospital treating all patients allocated to a specific HRG increases, the consequence
being that the HRG price collapses to cost-based reimbursement.
Subdividing HRGs cannot be adopted easily for those types of complex care where patients are distributed across many HRGs.
In these cases, prices rather than HRGs might be refined, with top-up payments made to reflect the additional costs associated
with receipt of complex care. Top-up payments can be made to either or both the base and excess per diem prices, according to
where the cost differentials are observed.
There are opportunities to improve on this work, notably by improving the cost data. There is a large U.S. literature analysing
hospital costs that relies on charge data (Frakt, 2011). RC data are analogous to the charge data reported to the Healthcare Cost
Report Information System.10 Neither U.S. charge data nor English RC data capture precisely the costs of care for each individual
patient (Dunham-Taylor & Pinczuk, 2006). The limitation of using RC data is that patients that share the same characteristics,
such as hospital, specialty, point of delivery, HRG, and LoS, will be assigned the same RC by their hospital. For the analysis,
this means that the RC data exhibit less variation than occurs in reality. If some of this unobserved variation is related to the
receipt of complex care, then the estimates of the cost differentials will be biased, most probably in a downward direction.
Recognising this limitation, we also analysed variation in LoS, but found that cost differentials are more likely to be observed
than LoS differentials (Bojke, Grašicˇ, & Street, 2015).
Patient-level information and costing systems (PLICS) could alleviate the drawback of using RC data, as patient-level costs
ought to take account of more specific drivers of resource use than do the RC. But PLICS will not resolve the problem entirely
because judgments still have to be made about how to apportion shared costs among individual patients (Jackson, 2001). Also,
on a practical level, PLICS will not be available in England for all patients in the near future. PLICS reporting is currently not
mandatory, and for the year of data, we consider (2013/14) only 53% of hospitals were reporting patient level costs11; and these
were not representative of the overall population of hospitals.12
As patient-level cost data become available, payment arrangements can be progressively refined. Refinements might involve
construction of more resource homogenous HRGs and better calculation of the base and excess per diem prices associated with
each HRG. In the meantime, our analyses indicate for which types of complex care services refinements are required to current
HRG prices so that policy ambitions to further the concentration of complex care services are not thwarted by an inadequate
payment system. The results have been used to inform hospital payment arrangements in England for 2016/17 (Monitor, 2015).
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